Ultralife (NASDAQ:ULBI – Get Free Report) released its quarterly earnings data on Thursday. The technology company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by ($0.09), FiscalAI reports. The business had revenue of $48.27 million during the quarter, compared to analyst estimates of $56.00 million. Ultralife had a negative net margin of 3.50% and a positive return on equity of 2.75%.
Ultralife Trading Up 0.2%
NASDAQ:ULBI opened at $15.66 on Friday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.30 and a current ratio of 2.87. Ultralife has a 52 week low of $4.90 and a 52 week high of $15.69. The stock’s 50 day moving average price is $7.60 and its 200 day moving average price is $6.69. The company has a market capitalization of $260.90 million, a P/E ratio of -82.42 and a beta of 0.63.
Analysts Set New Price Targets
Separately, Weiss Ratings restated a “sell (d)” rating on shares of Ultralife in a research note on Wednesday, September 9th. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.
Read Our Latest Stock Report on Ultralife
Ultralife Company Profile
Ultralife Corporation is a New York-based manufacturer of power and communications products serving government, defense, aerospace, industrial, medical and other specialized markets. The company develops and produces batteries, battery packs, chargers and related power-management products designed for portable and mission-critical equipment.
Ultralife’s product portfolio includes lithium primary and rechargeable batteries, custom battery assemblies, military battery systems, charging equipment and accessories.
See Also
- Five stocks we like better than Ultralife
- MarketBeat Week in Review – 11/2 – 11/6
- Q3 Earnings Have Investors Wondering: Is Mercado Libre Finally a Buy?
- CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?
- Array and Shoals Are Merging: Who Really Wins the All-Stock Solar Deal?
Receive News & Ratings for Ultralife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultralife and related companies with MarketBeat.com's FREE daily email newsletter.
